Scientific and technological innovation is accelerating the development of effective cancer vaccines, report Drs. Daina Vanags, Cori Gorman and Christian K. Schneider of Biopharma Excellence.
Barbara Arone, vice president, real world solutions, IQVIA, examines the ways biotech and emerging biopharma companies can effectively apply real world evidence (RWE) early in the product lifecycle while staying within their resource limits.
Jason Boyd, senior director, Vault LIMS, Veeva Systems, gives three ways in which digital strategies can modernise quality control by creating a holistic view of workflow and quality data in biopharma lab operations.
Penelope Drake, Ph.D., head of R&D, Bioconjugates, Catalent, highlights the potential of anti-body-drug conjugates in paving a way to innovation in oncology treatments.
Adam Clore, director of development & innovation at Integrated DNA Technologies, shares the achievements and objectives of mRNA vaccines; from the 1990s to the COVID-19 pandemic, and the hopes for the future.
Dr. Andreas Frerix dives into the challenges Asahi Kasei Bioprocess America (AKBA) faced in using pumping technology for handling inline buffer formulation and single-use virus filtration systems - finding a solution in quaternary diaphragm pumps.
EPM fired some quick questions with Juan Guerra, president of International Business Group at AmerisourceBergen, to learn about the increasing market for cold chain products and the future of the biopharma supply chain.
GSK, Sanofi and Takeda will partner with research communities from the Agency for Science, Technology and Research, NUS, NTU Singapore and SITT to boost Singapore's biologics manufacturing capabilities.
Lonza's Giovanna Libralon, Small Molecules, and Iwan Bertholjotti, Bioconjugates, share insights on payload-linker manufacturing and the global market trends for ADC-based therapies, along with the antibodies that help increase the precision of ADCs.
EPM sat with Marivi Mendizabal, vice president Quality and Regulatory, Cytiva, as she explains how government policy and regulatory trends impact the biopharma industry, and how collaborating with the government can enhance biopharma resilience.
Rebekah Jordan sits with Marty Gauvin, CEO of Fertilis, to discuss its IVF treatment innovation that replicates nature and automates the cell culture process, as well as its potential applications in regenerative medicine.
Portescap’s Jigar Fulia and Kanti Vala consider the selection criteria for biologics system motion solutions in delivery devices, and how this can help meet patient needs.
